• In Vitro Pharmacodynamics of Gamithromycin Against MmmSC

  2026-04-21

  This study provides the first detailed in vitro pharmacodynamic analysis of gamithromycin (ML-1709460) against Mycoplasma mycoides subsp. mycoides Small Colony, the causative agent of contagious bovine pleuropneumonia (CBPP). By rigorously comparing the antibiotic’s activity in artificial medium and bovine serum, the research clarifies matrix-driven potency shifts, informs PK/PD modeling, and positions gamithromycin as a candidate for future clinical assessment against CBPP.

• ZCL278: Precision Cdc42 Inhibition for Cellular Dynamics Res

  2026-04-21

  Explore the unique capabilities of ZCL278 as a selective Cdc42 inhibitor, with new insights into assay design, cellular signaling, and translational research. This article offers an advanced perspective not found in other resources.

• AR Heterogeneity Drives Distinct Therapy Responses in Prosta

  2026-04-20

  This study maps the heterogeneity of androgen receptor (AR) expression in castration-resistant prostate cancer (CRPC) and links it to differential responses to androgen deprivation and enzalutamide therapy. By integrating clinical specimen analysis, genome editing, and combinatorial treatment strategies, the research establishes AR status as a crucial determinant of therapeutic vulnerability and resistance, with implications for designing targeted interventions.

• MOG (35-55): Optimizing EAE and Neuroinflammation Assays

  2026-04-20

  MOG (35-55) Peptide empowers precise autoimmune encephalomyelitis research, bridging translational rigor with advanced neuroinflammation modeling. Learn how optimized protocols and emerging mechanistic insights from STAT pathway modulation transform multiple sclerosis studies.

• Triptolide (PG490): Precision Tools for Transcriptional Cont

  2026-04-19

  This thought-leadership article explores how Triptolide (PG490), a potent inhibitor of transcriptional machinery, empowers translational researchers to dissect and exploit transcriptional regulation in cancer and immunoinflammatory contexts. Integrating mechanistic insights, protocol recommendations, and strategic guidance, the article contextualizes recent discoveries on transcription condensate dynamics and positions APExBIO’s Triptolide as an indispensable tool for advanced experimental design.

• Scenario-Driven Laboratory Insights Using Minoxidil Sulphate

  2026-04-18

  This article delivers a practical, scenario-based guide for integrating high-purity Minoxidil sulphate (SKU C6513) into cell viability, proliferation, and vascular biology assays. Focusing on reproducibility, solubility, and validated performance, it demonstrates how Minoxidil sulphate from APExBIO empowers researchers to generate robust, publishable data while navigating typical experimental challenges.

• Spider Toxin v-Agatoxin-IVA Reveals Ca Channel Blockade Dive

  2026-04-17

  Sidach and Mintz’s study redefines the pharmacological selectivity of the spider toxin v-Agatoxin-IVA on neuronal calcium channels, demonstrating that its low-affinity blockade extends beyond classic P-type channels to include N-type and Q-type currents in mammalian neurons. These findings clarify the toxin’s practical limitations for functional channel classification and guide the design of selective pharmacological tools in neurophysiology.

• Nebivolol Hydrochloride: Assay Precision Beyond mTOR Interfe

  2026-04-16

  Explore Nebivolol hydrochloride as a highly selective β1-adrenoceptor antagonist for advanced cardiovascular research. This article uniquely analyzes its validated lack of mTOR pathway interference and offers strategic guidance for assay design.

• Cimetidine in Research: Mechanistic Insights and BBB Modelin

  2026-04-15

  Explore Cimetidine’s unique role as a histamine-2 receptor antagonist in cancer and blood-brain barrier research. This in-depth article reveals new mechanistic insights and practical assay guidance, distinguishing itself from existing reviews.

• PARP7 Inhibition Restores IFN-I Signaling and Relieves EAE i

  2026-04-14

  Xu et al. (2025) reveal that PARP7 suppresses type I interferon signaling by promoting autophagic degradation of STAT1/STAT2, and demonstrate that PARP7 inhibition alleviates neuroinflammatory symptoms in a mouse model of experimental autoimmune encephalomyelitis. This work identifies a novel regulatory mechanism of immune signaling with implications for multiple sclerosis research and potential therapeutic targeting.

• Brain-to-Spinal Circuits Regulate Mechanical Allodynia Later

  2026-04-13

  Huo et al. (2023) identify a specific contralateral brain-to-spinal circuit that controls both the laterality and duration of mechanical allodynia in mice. Their work reveals new neural pathways that modulate pain hypersensitivity, offering mechanistic insight for neurodegenerative and pain research.

• PERK–JAK1–STAT3 Pathway Drives Pyroptosis in Disc Degenerati

  2026-04-13

  This study reveals that endoplasmic reticulum stress (ERS) triggers pyroptosis in nucleus pulposus cells via PERK-dependent activation of the JAK1–STAT3 pathway, implicating this signaling axis as a driver of intervertebral disc degeneration. The findings highlight new therapeutic targets for modulating ERS-induced inflammation and cell death in disc disease.

• Plantaricin A Analogs Overcome Gram-Negative Antibiotic Resi

  2026-04-12

  Meng et al. (2022) demonstrate that Plantaricin A analogs, especially OP4, enhance the susceptibility of Gram-negative bacteria to hydrophobic antibiotics by increasing outer membrane permeability. This mechanistic advance offers a promising approach for addressing intrinsic antibiotic resistance and prolonging antibiotic efficacy in both in vitro and in vivo models.

• SP1/ADAM10/DRP1 Axis in Hypoxia Pulmonary Hypertension Cross

  2026-04-12

  This study uncovers a mechanistic axis—SP1/ADAM10/DRP1—that mediates the interaction between endothelial and smooth muscle cells under hypoxic pulmonary hypertension. By dissecting how ADAM10-driven signaling influences mitochondrial dynamics and cell fate, the research identifies new regulatory nodes and therapeutic targets for vascular remodeling.

• Rosiglitazone (Brl-49653): Applied Protocols for Adipogenesi

  2026-04-11

  Rosiglitazone (Brl-49653) is a benchmark tool for dissecting PPARγ-driven pathways in adipogenesis, insulin sensitivity, and metabolic disease models. This article presents actionable experimental workflows, troubleshooting guidance, and translational insights rooted in recent mechanistic breakthroughs, including the intersection with beige adipocyte differentiation.

16289 records 1/1086 page Next 12345 下5页 Last page